Engineering of a novel anti-CD40L domain antibody for treatment of autoimmune diseases

Journal of Immunology

Volumn 192, Issue 9, 2014, Pages 4083-4092

  Xie, Jenny H ^a   Yamniuk, Aaron P ^a   Borowski, Virna ^a   Kuhn, Robert ^a   Susulic, Vojkan ^a   Rex Rabe, Sandra ^a   Yang, Xiaoxia ^a   Zhou, Xiadi ^a   Zhang, Yifan ^a   Gillooly, Kathleen ^a   Brosius, Ruth ^a   Ravishankar, Rathna ^a   Waggie, Kimberly ^a   Mink, Kathy ^a   Price, Laura ^a   Rehfuss, Robert ^a   Tamura, James ^a   An, Yongmi ^a   Cheng, Lin ^a   Abramczyk, Bozena ^a   Ignatovich, Olga ^b   Drew, Philip ^b   Grant, Steven ^b   Bryson, James W ^a   Suchard, Suzanne ^a   Salter Cid, Luisa ^a   Nadler, Steven ^a   Suri, Anish ^a,c   more..

^a BRISTOL MYERS SQUIBB   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND; CD40 LIGAND DOMAIN ANTIBODY; CYTOKINE ANTIBODY; DUAL SPECIFICITY PHOSPHATASE 2; FC RECEPTOR; IMMUNOGLOBULIN G1; KEYHOLE LIMPET HEMOCYANIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MR 1; PADGEM PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY ENGINEERING; ANTIBODY RESPONSE; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE ACTIVATION; CARDIAC GRAFT REJECTION; CONTROLLED STUDY; DENDRITIC CELL; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; EMBRYO; FEMALE; HEART TRANSPLANTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUPUS ERYTHEMATOSUS; LUPUS VULGARIS; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; T LYMPHOCYTE; THROMBOCYTE ACTIVATION; THROMBOEMBOLISM;

ANIMALS; ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; CD40 LIGAND; DISEASE MODELS, ANIMAL; HEK293 CELLS; HUMANS; LYMPHOCYTE ACTIVATION; MICE; PLATELET ACTIVATION; RECEPTORS, IGG; SINGLE-DOMAIN ANTIBODIES; SURFACE PLASMON RESONANCE; THROMBOEMBOLISM; TRANSFECTION;

EID: 84899515806     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1303239     Document Type: Article

References (36)

1. Ashokkumar, C., A. Talukdar, Q. Sun, B. W. Higgs, J. Janosky, P. Wilson, G. Mazariegos, R. Jaffe, A. Demetris, J. Dobberstein, et al. 2009. Allospecific CD154+ T cells associate with rejection risk after pediatric liver transplantation. Am. J. Transplant. 9: 179-191
2. Biancone, L., G. Segoloni, E. Turello, D. Donati, B. Bussolati, G. Piccoli, and G. Camussi. 1998. Expression of inducible lymphocyte costimulatory molecules in human renal allograft. Nephrol. Dial. Transplant. 13: 716-722
3. Danese, S., J. A. Katz, S. Saibeni, A. Papa, A. Gasbarrini, M. Vecchi, and C. Fiocchi. 2003. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut 52: 1435-1441
4. Duffau, P., J. Seneschal, C. Nicco, C. Richez, E. Lazaro, I. Douchet, C. Bordes, J. F. Viallard, C. Goulvestre, J. L. Pellegrin, et al. 2010. Platelet CD154 potentiates interferon-alpha secretion by plasmacytoid dendritic cells in systemic lupus erythematosus. Sci. Transl. Med. 2: 47ra63
5. Kimura, K., H. Tsuda, Y. Kwangseok, N. Tamura, Y. Kanai, and S. Kobayashi. 2005. Study of plasma levels of soluble CD40 ligand in systemic lupus erythematosus patients who have unDergone plasmapheresis. Ther. Apher. Dial. 9: 64-68
6. Komura, K., S. Sato, M. Hasegawa, M. Fujimoto, and K. Takehara. 2004. Elevated circulating CD40L concentrations in patients with systemic sclerosis. J. Rheumatol. 31: 514-519
7. LeDerer, S. R., N. Friedrich, R. Gruber, R. Landgraf, M. Toepfer, and T. Sitter. 2004. Reduced CD40L expression on ex vivo activated CD4+ T-lymphocytes from patients with excellent renal allograft function measured with a rapid whole blood flow cytometry procedure. Int. Arch. Allergy Immunol. 133: 276-284
8. Ludwiczek, O., A. Kaser, and H. Tilg. 2003. Plasma levels of soluble CD40 ligand are elevated in inflammatory bowel diseases. Int. J. Colorectal Dis. 18: 142-147
9. Prahalad, S., T. B. Martins, A. E. Tebo, A. Whiting, B. Clifford, A. S. Zeft, B. McNally, J. F. Bohnsack, and H. R. Hill. 2008. Elevated serum levels of soluble CD154 in children with juvenile idiopathic arthritis. Pediatr. Rheumatol. Online J. 6: 8
10. Sellam, J., V. Proulle, A. Jungel, M. Ittah, C. Miceli Richard, J. E. Gottenberg, F. Toti, J. Benessiano, S. Gay, J. M. Freyssinet, and X. Mariette. 2009. Increased levels of circulating microparticles in primary Sjögren?s syndrome, systemic lupus erythematosus and rheumatoid arthritis and relation with disease activity. Arthritis Res. Ther. 11: R156
11. Tousoulis, D., E. Androulakis, N. Papageorgiou, A. Briasoulis, G. Siasos, C. Antoniades, and C. Stefanadis. 2010. From atherosclerosis to acute coronary syndromes: The role of soluble CD40 ligand. Trends Cardiovasc. Med. 20: 153-164
12. Vakkalanka, R. K., C. Woo, K. A. Kirou, M. Koshy, D. Berger, and M. K. Crow. 1999. Elevated levels and functional capacity of soluble CD40 ligand in systemic lupus erythematosus sera. Arthritis Rheum. 42: 871-881
13. Aruffo, A., M. Farrington, D. Hollenbaugh, X. Li, A. Milatovich, S. Nonoyama, J. Bajorath, L. S. Grosmaire, R. Stenkamp, M. Neubauer, et al. 1993. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper- IgM syndrome. Cell 72: 291-300
14. Fuleihan, R., N. Ramesh, R. Loh, H. Jabara, R. S. Rosen, T. Chatila, S. M. Fu, I. Stamenkovic, and R. S. Geha. 1993. Defective expression of the CD40 ligand in X chromosome-linked immunoglobulin deficiency with normal or elevated IgM. Proc. Natl. Acad. Sci. USA 90: 2170-2173
15. Elgueta, R., M. J. Benson, V. C. de Vries, A. Wasiuk, Y. Guo, and R. J. Noelle. 2009. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol. Rev. 229: 152-172
16. Patel, V. L., J. Schwartz, and J. B. Bussel. 2008. The effect of anti-CD40 ligand in immune thrombocytopenic purpura. Br. J. Haematol. 141: 545-548
17. Boumpas, D. T., R. Furie, S. Manzi, G. G. Illei, D. J. Wallace, J. E. Balow, and A. Vaishnaw; BG9588 Lupus Nephritis Trial Group. 2003. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 48: 719-727
18. Robles-Carrillo, L., T. Meyer, M. Hatfield, H. Desai, M. Dávila, F. Langer, M. Amaya, E. Garber, J. L. Francis, Y. M. Hsu, and A. Amirkhosravi. 2010. Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice. J. Immunol. 185: 1577-1583
19. Ferrant, J. L., C. D. Benjamin, A. H. Cutler, S. L. Kalled, Y. M. Hsu, E. A. Garber, D. M. Hess, R. I. Shapiro, N. S. Kenyon, D. M. Harlan, et al. 2004. The contribution of Fc effector mechanisms in the efficacy of anti-CD154 immunotherapy depends on the nature of the immune challenge. Int. Immunol. 16: 1583-1594
20. Daley, S. R., S. P. Cobbold, and H. Waldmann. 2008. Fc-disabled anti-mouse CD40L antibodies retain efficacy in promoting transplantation tolerance. Am. J. Transplant. 8: 2265-2271
21. Holt, L. J., C. Herring, L. S. Jespers, B. P. Woolven, and I. M. Tomlinson. 2003. Domain antibodies: Proteins for therapy. Trends Biotechnol. 21: 484-490
22. Gay, R. D., A. W. Clarke, Z. Elgundi, T. Domagala, R. J. Simpson, N. B. Le, A. G. Doyle, and P. A. Jennings. 2010. Anti-TNFa domain antibody construct CEP-37247: Full antibody functionality at half the size. MAbs 2: 625-638
23. Suchard, S. J., P. M. Davis, S. Kansal, D. K. Stetsko, R. Brosius, J. Tamura, L. Schneeweis, J. Bryson, T. Salcedo, H. Wang, et al. 2013. A monovalent antihuman CD28 domain antibody antagonist: Preclinical efficacy and safety. J. Immunol. 191: 4599-4610
24. Holt, L. J., A. Basran, K. Jones, J. Chorlton, L. S. Jespers, N. D. Brewis, and I. M. Tomlinson. 2008. Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs. Protein Eng. Des. Sel. 21: 283-288
25. Pham, P. L., A. Kamen, and Y. Durocher. 2006. Large-scale transfection of mammalian cells for the fast production of recombinant protein. Mol. Biotechnol. 34: 225-237
26. Matsuura, J. E., A. E. Morris, R. R. Ketchem, E. H. Braswell, R. Klinke, W. R. Gombotz, and R. L. Remmele, Jr. 2001. Biophysical characterization of a soluble CD40 ligand (CD154) coiled-coil trimer: Evidence of a reversible aciddenatured molten globule. Arch. Biochem. Biophys. 392: 208-218
27. Karpusas, M., J. Lucci, J. Ferrant, C. Benjamin, F. R. Taylor, K. Strauch, E. Garber, and Y. M. Hsu. 2001. Structure of CD40 ligand in complex with the Fab fragment of a neutralizing humanized antibody. Structure 9: 321-329
28. Jiang, C., J. Foley, N. Clayton, G. Kissling, M. Jokinen, R. Herbert, and M. Diaz. 2007. Abrogation of lupus nephritis in activation-induced deaminase-deficient MRL/lpr mice. J. Immunol. 178: 7422-7431
29. Linsley, P. S., W. Brady, M. Urnes, L. S. Grosmaire, N. K. Damle, and J. A. Ledbetter. 1991. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 174: 561-569
30. Davis, P. M., R. Abraham, L. Xu, S. G. Nadler, and S. J. Suchard. 2007. Abatacept binds to the Fc receptor CD64 but does not mediate complementdependent cytotoxicity or antibody-dependent cellular cytotoxicity. J. Rheumatol. 34: 2204-2210
31. Ignatovich, O., L. Jespers, I. M. Tomlinson, and R. M. de Wildt. 2012. Creation of the large and highly functional synthetic repertoire of human VH and Vk domain antibodies. Methods Mol. Biol. 911: 39-63
32. Ferrant, J. L., C. A. Wilson, C. D. Benjamin, D. M. Hess, Y. M. Hsu, M. Karpusas, K. H. Roux, and F. R. Taylor. 2002. Variation in the orDered structure of complexes between CD154 and anti-CD154 monoclonal antibodies. Mol. Immunol. 39: 77-84
33. Kohno, T., L. T. Tam, S. R. Stevens, and J. S. Louie. 2007. Binding characteristics of tumor necrosis factor receptor-Fc fusion proteins vs anti-tumor necrosis factor mAbs. J. Investig. Dermatol. Symp. Proc. 12: 5-8
34. Scallon, B., A. Cai, N. Solowski, A. Rosenberg, X. Y. Song, D. Shealy, and C. Wagner. 2002. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J. Pharmacol. Exp. Ther. 301: 418-426
35. Baudino, L., Y. Shinohara, F. Nimmerjahn, J. Furukawa, M. Nakata, E. Martínez-Soria, F. Petry, J. V. Ravetch, S. Nishimura, and S. Izui. 2008. Crucial role of aspartic acid at position 265 in the CH2 domain for murine IgG2a and IgG2b Fc-associated effector functions. J. Immunol. 181: 6664-6669
36. Pinelli, D. F., M. E. Wagener, D. Liu, A. Yamniuk, J. Tamura, S. Grant, C. P. Larsen, A. Suri, S. G. Nadler, and M. L. Ford. 2013. An anti-CD154 domain antibody prolongs graft survival and induces Foxp3(+) iTreg in the absence and presence of CTLA-4 Ig. Am. J. Transplant. 13: 3021-3030